10-Q: Agentix Corp. Faces Going Concern Doubt Amid Mounting Losses

Agentix Corp. reports significant financial distress with a substantial doubt about its ability to continue as a going concern, marked by increasing net losses and negative working capital.

Summary

• Agentix Corp. reported a net loss of $408,526 for the nine months ended December 31, 2025, compared to a net loss of $385,280 for the same period in 2024.
• Cash on hand as of December 31, 2025, was critically low at $6,396, down from $4,477 at March 31, 2025, and $8,273 at December 31, 2024.
• Total liabilities increased to $3,504,396 as of December 31, 2025, from $3,204,523 at March 31, 2025.
• The company has an accumulated deficit of $6,930,054 and a total stockholders' deficit of $3,498,000 as of December 31, 2025.
• Operating activities used $123,305 in cash for the nine months ended December 31, 2025, an increase from $82,020 used in the prior year period.
• Professional fees increased to $214,536 for the nine months ended December 31, 2025, up from $197,942 in the prior year, primarily due to higher accounting, legal, and consulting support.
• Research and development expenses rose to $125,079 for the nine months ended December 31, 2025, from $90,638 in the prior year, driven by increased R&D consulting and project activity.
• The company recorded no revenues for both the three and nine months ended December 31, 2025, and 2024.
• Disclosure controls and procedures were deemed not effective as of December 31, 2025.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this as extremely negative. The explicit 'going concern' warning, critically low cash, increasing losses, and ineffective disclosure controls paint a dire financial picture with high risk of business failure.

Positives

• General and administrative expenses decreased slightly to $51,287 for the nine months ended December 31, 2025, from $52,550 in the prior year, reflecting cost controls.
• A foreign exchange gain of $20,961 was recorded for the nine months ended December 31, 2025, compared to a loss of $15,376 in the prior year.
• Other income of $20,604 was recognized from the settlement of accounts payable for the nine months ended December 31, 2025.

Negatives

• The company's cash position of $6,396 is insufficient to support daily operations, raising substantial doubt about its ability to continue as a going concern.
• Net loss increased to $408,526 for the nine months ended December 31, 2025, from $385,280 in the prior year.
• Total liabilities increased, with significant amounts owed to related parties, including $1,430,978 to SBS Management LLC, $518,397 to Grays Peak Capital, and $433,497 to management.
• Interest expense, net, increased to $59,189 for the nine months ended December 31, 2025, from $28,774 in the prior year, due to higher average debt balances.
• The company has negative working capital and negative cash flows from operating activities.
• Disclosure controls and procedures were not effective as of December 31, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to an accumulated deficit, net loss, negative cash flows from operating activities, and negative working capital.
• The company's cash position is not sufficient to support daily operations, necessitating further funding.
• Inability to raise additional funds through equity or debt financing could lead to the failure of the business.
• Equity financing would result in dilution for existing shareholders, while debt financing may have unfavorable terms.
• The company's disclosure controls and procedures were not effective, indicating potential weaknesses in financial reporting oversight.

Future Outlook

The company's ability to continue as a going concern is dependent on its capacity to implement its business plan, generate sufficient revenue, and raise additional funds. Management anticipates that additional funding will likely come from equity financing through the sale of common stock or debt financing. However, there is no assurance that sufficient funding can be raised, and without it, the business will likely fail, leading to potential dilution for existing shareholders if equity financing is successful, or unfavorable terms if debt financing is secured.

Management Comments

• Management has included projections and estimates in this Form 10-Q, which are based primarily on management's experience in the industry, assessments of results of operations, discussions and negotiations with third parties, and a review of information filed by competitors.
• Management cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made, and disclaims any obligation to revise them subsequently.
• Management concluded that disclosure controls and procedures were not effective as of December 31, 2025.

Industry Context

StockSavvy.ai notes that Agentix Corp. operates in the highly capital-intensive clinical-stage biotechnology sector, focusing on metabolic diseases. Companies at this stage typically require substantial and continuous funding for research, development, and clinical trials, often without generating revenue. The current financial state, characterized by minimal cash, increasing losses, and a 'going concern' warning, is a critical indicator of the significant challenges faced by early-stage biotech firms, especially those struggling to secure adequate financing to advance their therapeutic agents.

Comparison to Industry Standards

• The company's lack of revenue is typical for a clinical-stage biotechnology company, as product commercialization is still in the future.
• The accumulated deficit and negative cash flow from operations are common for biotech companies in the R&D phase, but the severity and the explicit 'going concern' warning indicate a more precarious financial position compared to peers with stronger funding pipelines or more advanced clinical programs.
• The reliance on related-party debt and advances, which constitute a significant portion of total liabilities, suggests difficulty in securing traditional third-party financing, a common challenge for distressed smaller companies, unlike well-capitalized industry leaders such as Eli Lilly or Novo Nordisk, which have robust R&D budgets and diverse funding sources.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• SBS Management LLC, controlled by a shareholder, received $265,487 in management consulting fees and made advances to the company during the nine months ended December 31, 2025. $1,430,978 was owed to SBS Management LLC as of December 31, 2025.
• Grays Peak Capital, founded by a shareholder, made advances to cover operating expenses. $518,397 was owed to Grays Peak Capital as of December 31, 2025.
• Grays Peak Private Credit LLC provided a Mezzanine Secured Note with a principal balance of $353,450 outstanding as of December 31, 2025. This note bears interest at 2% per month after 30 days and is secured by all company assets. The maturity date has been extended to June 30, 2026.
• Management was owed $433,497 as of December 31, 2025, included in accounts payable related parties.

Stakeholder Impact

• Shareholders face a high risk of significant dilution if the company successfully raises equity capital, or a complete loss of investment if the company fails to secure necessary funding and ceases operations.
• Creditors, particularly related parties, bear substantial risk given the company's 'going concern' issues and the significant amounts owed.
• Employees (if any beyond management) face job insecurity due to the company's precarious financial position.

Next Steps

• The company is attempting to commence operations and generate sufficient revenue.
• The company needs to raise additional funds to support daily operations and fund ongoing operational expenses for the next 12 months.
• Management needs to address the ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

The filing presents an extremely concerning financial outlook, with an explicit 'going concern' warning, critically low cash reserves ($6,396), increasing net losses, and negative working capital. The company's inability to generate revenue, coupled with its reliance on related-party debt and the acknowledged ineffectiveness of disclosure controls, indicates severe operational and financial instability. Without a clear path to substantial funding, the risk of business failure is exceptionally high, making the stock a strong sell for any seasoned investor or institution.

Keywords

Agentix Corp, 10-Q, Quarterly Report, Biotechnology, Clinical-stage, Metabolic disease, Type 2 diabetes, Obesity, NAFLD, NASH, Going concern, Net loss, Cash flow, Liabilities, Related party transactions, SEC filing, Financial distress, Capital raise